JP2021500880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500880A5 JP2021500880A5 JP2020521360A JP2020521360A JP2021500880A5 JP 2021500880 A5 JP2021500880 A5 JP 2021500880A5 JP 2020521360 A JP2020521360 A JP 2020521360A JP 2020521360 A JP2020521360 A JP 2020521360A JP 2021500880 A5 JP2021500880 A5 JP 2021500880A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- adenovirus vector
- expression cassette
- monkey adenovirus
- saladenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000701161 unidentified adenovirus Species 0.000 claims description 38
- 241000282693 Cercopithecidae Species 0.000 claims description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 230000001124 posttranscriptional effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 241001217856 Chimpanzee adenovirus Species 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572944P | 2017-10-16 | 2017-10-16 | |
| US62/572,944 | 2017-10-16 | ||
| PCT/EP2018/078210 WO2019076880A1 (en) | 2017-10-16 | 2018-10-16 | SIMIENS ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500880A JP2021500880A (ja) | 2021-01-14 |
| JP2021500880A5 true JP2021500880A5 (enExample) | 2021-11-25 |
Family
ID=63896161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521360A Ceased JP2021500880A (ja) | 2017-10-16 | 2018-10-16 | ２つの発現カセットを有するサルアデノウイルスベクター |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200299651A1 (enExample) |
| EP (1) | EP3697918B1 (enExample) |
| JP (1) | JP2021500880A (enExample) |
| CN (1) | CN111479926A (enExample) |
| AR (1) | AR114989A1 (enExample) |
| BR (1) | BR112020007413A2 (enExample) |
| CA (1) | CA3084346A1 (enExample) |
| MX (1) | MX2020003746A (enExample) |
| WO (1) | WO2019076880A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| CA3168100A1 (en) * | 2020-01-28 | 2021-08-05 | Codagenix Inc. | Deoptimized sars-cov-2 and methods and uses thereof |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| EP1743028A2 (en) * | 2004-04-28 | 2007-01-17 | The Trustees Of The University Of Pennsylvania | Polyvalent viral vectors and a system for production thereof |
| US8883493B2 (en) | 2007-01-30 | 2014-11-11 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
| US20100203071A1 (en) | 2007-03-21 | 2010-08-12 | Norman Blais | Chimeric antigens |
| CN107026511A (zh) | 2008-09-27 | 2017-08-08 | 韦特里西提公司 | 无线能量转移系统 |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| WO2013052859A2 (en) * | 2011-10-05 | 2013-04-11 | Genvec, Inc. | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine |
| CN106659777A (zh) * | 2014-06-13 | 2017-05-10 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合产品 |
| EA038402B9 (ru) | 2015-06-12 | 2021-09-22 | Глаксосмитклайн Байолоджикалс Са | Аденовирусные полинуклеотиды и полипептиды |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| WO2018060288A1 (en) | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
-
2018
- 2018-10-16 CN CN201880081337.6A patent/CN111479926A/zh active Pending
- 2018-10-16 BR BR112020007413-6A patent/BR112020007413A2/pt not_active IP Right Cessation
- 2018-10-16 WO PCT/EP2018/078210 patent/WO2019076880A1/en not_active Ceased
- 2018-10-16 EP EP18789094.2A patent/EP3697918B1/en active Active
- 2018-10-16 US US16/756,377 patent/US20200299651A1/en not_active Abandoned
- 2018-10-16 MX MX2020003746A patent/MX2020003746A/es unknown
- 2018-10-16 JP JP2020521360A patent/JP2021500880A/ja not_active Ceased
- 2018-10-16 AR ARP180103001A patent/AR114989A1/es not_active Application Discontinuation
- 2018-10-16 CA CA3084346A patent/CA3084346A1/en not_active Abandoned
-
2023
- 2023-08-21 US US18/453,078 patent/US12180512B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang | Adenovirus vectors: excellent tools for vaccine development | |
| JP2017514483A5 (enExample) | ||
| JP2021500880A5 (enExample) | ||
| CN103998604B (zh) | Hbv聚合酶突变体 | |
| JP2014516536A5 (enExample) | ||
| JP2014512171A5 (enExample) | ||
| RU2016146664A (ru) | Аденовирус, содержащий альбумин-связывающий участок | |
| JP2016538885A5 (enExample) | ||
| JP2014503206A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| JP2018537984A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2015506179A5 (enExample) | ||
| CA2863964A1 (en) | Compartmentalized method of nucleic acid delivery and compositions and uses thereof | |
| RU2019100525A (ru) | Векторная система на основе аденоассоциированного вируса | |
| CN113226364A (zh) | 组合物和方法 | |
| Nguyen et al. | Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers | |
| JP2020537525A5 (enExample) | ||
| JP2020537526A5 (enExample) | ||
| Bisgin et al. | Current update on severe acute respiratory syndrome coronavirus 2 vaccine development with a special emphasis on gene therapy viral vector design and construction for vaccination | |
| Penghui et al. | Oncolytic activity of a novel influenza A virus carrying granulocyte-macrophage colony-stimulating factor in hepatocellular carcinoma | |
| JP2020527167A5 (enExample) | ||
| JP2018526994A5 (enExample) | ||
| Nistal-Villan et al. | Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model |